Vaxcyte, Inc. (Nasdaq: PCVX) announced positive topline results from OPUS-1, a pivotal adult Phase 3 trial evaluating VAX-31, its 31-valent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE